FDA Warns Stryker Again Over Quality Control
On Friday, the Kalamazoo, Mich.-based medical technology company revealed that its Biotech unit had received a warning letter from the FDA. The letter concerned Stryker's quality systems and compliance issues at its Hopkinton, Mass., facility. No recalls were connected with the letter, Stryker said.
The letter, which cited observations made by...
To view the full article, register now.